IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
AstraZeneca eyes Bristol Myers merger, creating $400B oncology powerhouse
AstraZeneca is discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal would value the combined pharmaceutical giant at nearly $400...
AstraZeneca eyes $400B Bristol Myers Squibb merger, targeting oncology dominance
Britain's AstraZeneca is reportedly discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal values the combined company at nearly $400...
AstraZeneca and Bristol Myers Squibb in Talks for Potential $400B Mega-Merger
Britain's AstraZeneca is reportedly in discussions to merge with U.S. rival Bristol Myers Squibb in a deal that would create a pharmaceutical giant valued at...
Novartis Pluvicto Wins FDA Approval for Earlier Use, Doubling Patient Pool
The U.S. Food and Drug Administration (FDA) expanded the approval for Novartis’s targeted radioligand therapy, Pluvicto. The FDA now authorizes the drug for...
J&J secures $2.58B option for Sail Biomedicines, targeting in-body cell therapy
Johnson & Johnson secured an option to acquire Sail Biomedicines for up to $2.58 billion. This investment targets Sail’s novel in vivo chimeric antigen...
Argenx buys Forte Biosciences for $2.2B, targeting major autoimmune breakthrough
Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at $2.2 billion. The offer of $77 per share represents a significant premium for...
Argenx Buys Forte Biosciences for $2.2B, Expanding Autoimmune Pipeline
Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion. The offer price of $77 per share represents a 40.5%...
AstraZeneca Beats Q2 Profit Estimates, Boosts Dividend on Oncology Strength
AstraZeneca exceeded second-quarter 2026 profit expectations and reaffirmed its annual guidance. Core earnings reached $2.63 per share, surpassing the $2.48...
Kenvue Wins FDA Approval for Tylenol-Aleve Pill, Securing 3-Year Market Exclusivity
The U.S. Food and Drug Administration (FDA) approved Kenvue’s new over-the-counter (OTC) pain medication. This first-of-its-kind tablet combines acetaminophen,...
🟢 IYH is trading 5.3% up today on generic drug tariff plans and GSK FDA approval
IYH is trading 5.3% up today as healthcare stocks rally in response to shifting U.S. drug policies and key regulatory milestones. • Sentiment is being driven...
GSK Wins FDA Approval for Jideytro, Validating $10.6B Nuvalent Deal
The U.S. Food and Drug Administration approved GSK’s Jideytro (zidesamtinib) for adult patients with ROS1-positive advanced non-small cell lung cancer. This...
Johnson & Johnson Enters Robotic Surgery Market with FDA-Authorized OTTAVA System
Johnson & Johnson MedTech received FDA De Novo authorization for its OTTAVA Robotic Surgical System. The technology is the first robotic system integrated...
Danaher shares tumble 9%, weighed down by soft third-quarter growth forecast
Danaher Corporation (NYSE: DHR) reported second-quarter revenue of $6.3 billion. Adjusted earnings per share reached $1.94, surpassing analyst expectations....
Eli Lilly acquires AtaiBeckley for $3.8B, targeting depression with psychedelic drugs
Eli Lilly agreed to acquire biopharmaceutical firm AtaiBeckley for up to $3.8 billion. The deal marks Lilly’s first major expansion into the psychedelic drug...
Eli Lilly buys AtaiBeckley for $3.8B, expanding into psychedelic depression treatments
Eli Lilly agreed to acquire clinical-stage AtaiBeckley for up to $3.8 billion. The transaction consists of a $2.8 billion upfront cash payment and up to $1...
HCA Healthcare Raises 2026 Outlook, Citing Strong Q2 Revenue Growth
HCA Healthcare reported preliminary second-quarter results that exceeded analyst expectations. The company anticipates Q2 revenue of approximately $20.23...
HCA Healthcare raises 2026 outlook, fueled by $20.23 billion Q2 revenue
HCA Healthcare reported preliminary second-quarter results that exceeded market expectations. The company projects Q2 revenue of approximately $20.23 billion,...
Novo Nordisk advances hemophilia drug denecimig, expanding rare disease portfolio
Novo Nordisk announced positive Phase 3 results for denecimig (Mim8), an investigational hemophilia A treatment. The company presented the FRONTIER4 long-term...
Sanofi wins FDA approval for wearable Sarclisa, cutting myeloma treatment time
The U.S. Food and Drug Administration (FDA) approved a subcutaneous version of Sanofi’s multiple myeloma drug, Sarclisa (isatuximab-irfc). This new formulation...
Ionis and AstraZeneca Fail Phase 3, Stalling Lucrative Eplontersen Expansion
Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced today that their Phase 3 CARDIO-TTRansform trial for eplontersen failed its primary endpoint....